Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Belzutifan for cancers associated with von Hippel-Lindau disease - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Altai Protocol Library October 4, 2021

New Drug: Belzutifan for cancers associated with von Hippel-Lindau disease

New Drug: Belzutifan for cancers associated with von Hippel-Lindau disease
Study:	Open label Phase II trial (Study 004) Adults with germline vHL alterations with clear-cell RCC (N=61). Pts had other vHL-associated tumors: 12 pts had measurable pNET, 24 pts had measurable CNS hemangioblastoma Belzutifan 120 mg PO daily
Efficacy:	ORR: 49% (ccRCC), 83% (pNET), 63% (CNS hemangioblastoma) 56% of responders with ccRCC had DoR over one year
Safety:	All pts had AEs. No Grade 4 AEs reported. Most common AE was anemia (90%) with grade 3 anemia in 7%
J Clin Oncol 2021;39: suppl 4555. Srinivasan R, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) https://doi.org/10.1200/JCO.2021.39.15_suppl.4555

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.